JP2011512189A - 患者に対する薬物の投与 - Google Patents
患者に対する薬物の投与 Download PDFInfo
- Publication number
- JP2011512189A JP2011512189A JP2010546431A JP2010546431A JP2011512189A JP 2011512189 A JP2011512189 A JP 2011512189A JP 2010546431 A JP2010546431 A JP 2010546431A JP 2010546431 A JP2010546431 A JP 2010546431A JP 2011512189 A JP2011512189 A JP 2011512189A
- Authority
- JP
- Japan
- Prior art keywords
- drug
- patient
- delivery
- administration
- pill
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940079593 drug Drugs 0.000 title claims abstract description 102
- 239000003814 drug Substances 0.000 title claims abstract description 102
- 239000006187 pill Substances 0.000 claims abstract description 56
- 238000000034 method Methods 0.000 claims abstract description 35
- 210000001035 gastrointestinal tract Anatomy 0.000 claims abstract description 25
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 7
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 7
- 230000004044 response Effects 0.000 claims description 19
- 238000012377 drug delivery Methods 0.000 claims description 14
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 claims description 9
- 238000001647 drug administration Methods 0.000 claims description 9
- 238000004590 computer program Methods 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 7
- 102000018832 Cytochromes Human genes 0.000 claims description 6
- 108010052832 Cytochromes Proteins 0.000 claims description 6
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 claims description 4
- 102000014842 Multidrug resistance proteins Human genes 0.000 claims description 4
- 108050005144 Multidrug resistance proteins Proteins 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 4
- 210000002700 urine Anatomy 0.000 claims description 4
- 230000005540 biological transmission Effects 0.000 claims description 3
- 238000005259 measurement Methods 0.000 abstract description 6
- 238000010521 absorption reaction Methods 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 239000000203 mixture Substances 0.000 description 10
- 101150051438 CYP gene Proteins 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 102000004328 Cytochrome P-450 CYP3A Human genes 0.000 description 8
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 230000000968 intestinal effect Effects 0.000 description 7
- 230000004060 metabolic process Effects 0.000 description 7
- 230000008685 targeting Effects 0.000 description 6
- 101001017818 Homo sapiens ATP-dependent translocase ABCB1 Proteins 0.000 description 5
- 210000003405 ileum Anatomy 0.000 description 5
- 230000001839 systemic circulation Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 4
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 230000029142 excretion Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108010078791 Carrier Proteins Proteins 0.000 description 3
- 229940123237 Taxane Drugs 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000011260 co-administration Methods 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 210000001198 duodenum Anatomy 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 210000001630 jejunum Anatomy 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- 102100022595 Broad substrate specificity ATP-binding cassette transporter ABCG2 Human genes 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 101000823298 Homo sapiens Broad substrate specificity ATP-binding cassette transporter ABCG2 Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 2
- 229960003773 calcitonin (salmon synthetic) Drugs 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002702 enteric coating Substances 0.000 description 2
- 238000009505 enteric coating Methods 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 238000010579 first pass effect Methods 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108010068072 salmon calcitonin Proteins 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010033372 Pain and discomfort Diseases 0.000 description 1
- UJEWTUDSLQGTOA-UHFFFAOYSA-N Piretanide Chemical compound C=1C=CC=CC=1OC=1C(S(=O)(=O)N)=CC(C(O)=O)=CC=1N1CCCC1 UJEWTUDSLQGTOA-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 238000012382 advanced drug delivery Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960000794 baclofen Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000009535 clinical urine test Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 229940124301 concurrent medication Drugs 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- -1 degradable matrices Substances 0.000 description 1
- 229920006237 degradable polymer Polymers 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
- 229960005156 digoxin Drugs 0.000 description 1
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 229950005476 elacridar Drugs 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 230000007614 genetic variation Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 1
- 229960002237 metoprolol Drugs 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 description 1
- 229960003793 midazolam Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000003232 mucoadhesive effect Effects 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- OSFCMRGOZNQUSW-UHFFFAOYSA-N n-[4-[2-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)ethyl]phenyl]-5-methoxy-9-oxo-10h-acridine-4-carboxamide Chemical compound N1C2=C(OC)C=CC=C2C(=O)C2=C1C(C(=O)NC1=CC=C(C=C1)CCN1CCC=3C=C(C(=CC=3C1)OC)OC)=CC=C2 OSFCMRGOZNQUSW-UHFFFAOYSA-N 0.000 description 1
- 229940127084 other anti-cancer agent Drugs 0.000 description 1
- 230000004783 oxidative metabolism Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229960001085 piretanide Drugs 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000007425 progressive decline Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001578 tight junction Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000816 toxic dose Toxicity 0.000 description 1
- 210000002438 upper gastrointestinal tract Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
- A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/07—Endoradiosondes
- A61B5/073—Intestinal transmitters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14539—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring pH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4836—Diagnosis combined with treatment in closed-loop systems or methods
- A61B5/4839—Diagnosis combined with treatment in closed-loop systems or methods combined with drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/42—Detecting, measuring or recording for evaluating the gastrointestinal, the endocrine or the exocrine systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/35—Communication
- A61M2205/3507—Communication with implanted devices, e.g. external control
- A61M2205/3523—Communication with implanted devices, e.g. external control using telemetric means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/50—General characteristics of the apparatus with microprocessors or computers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2210/00—Anatomical parts of the body
- A61M2210/10—Trunk
- A61M2210/1042—Alimentary tract
- A61M2210/1053—Stomach
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2210/00—Anatomical parts of the body
- A61M2210/10—Trunk
- A61M2210/1042—Alimentary tract
- A61M2210/1053—Stomach
- A61M2210/1057—Duodenum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2210/00—Anatomical parts of the body
- A61M2210/10—Trunk
- A61M2210/1042—Alimentary tract
- A61M2210/106—Small intestine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Heart & Thoracic Surgery (AREA)
- Surgery (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Optics & Photonics (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Medicinal Preparation (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Abstract
Description
ePill20内に所定の薬物送達プロファイルをプログラムするプログラミングステーション10、11と、
摂取可能なePill20のセットと、
患者1の消化管の通過中にピル20からデータを無線で集めるポータブルユニット30と、
ポータブルユニット30からデータを集めるホームベースステーション40と、
医師のような関係者のコンピュータ60に前記ピルデータを転送するネットワーク50と、
を含む。
薬物治療に対する予測される患者応答(代謝、排出)を特徴付けるステップと、
例えば酵素活性の濃度又は関連したレセプタの発現により前記患者の腸管内の予測される吸収プロファイルをマッピングするステップと、
場所に対する吐出速度の薬物送達プロファイルを作成するステップと、
前記ePillを投与するステップと、
薬物動態データを集める又は応答をモニタするステップと、
送達プロファイルを調節し、必要に応じて前記ePillの投与から繰り返すステップと、
を採用する。
例えばマイクロプロセッサに埋め込まれたフラッシュメモリ又はRAMにより実現される、プログラム可能なメモリMEMと、
(とりわけ)リザーバ26からの薬物3の送達を制御する、例えばマイクロコンピュータにより実現される、コントローラCONと、
例えばCYP又はpHに対する、少なくとも1つのセンサSENと、
外部装置と無線通信する受信器/送信器Rx/Txと、
を有する。
前記患者の遺伝子型GEN、
腸ターゲティングを可能にする、前記患者の消化管GIT内の標的領域の指定、
前記薬物の以前の投与の間の前記患者の応答を含む薬物動態データBLD、
に基づきうる。
Claims (10)
- 患者に少なくとも1つの薬物を投与する方法において、前記患者の少なくとも1つの個人用パラメータによって決定される送達プロファイルを用いる電子ピルによる前記薬物の送達を有する方法。
- 前記個人用パラメータが、
特にシトクロム発現に関する、前記患者の遺伝子型の一部、
特に前記患者の消化管内の特定のタンパク質の発現に関する、前記患者の表現型の一部、
前記投与される薬物に関連した前記患者の身体内の物質、特に血液、尿、又は呼気内の物質、の量、
薬物動態データ及び/又は前記薬物投与に対する前記患者の応答、
共投与薬物のプロファイル、
の少なくとも1つを有することを特徴とする、
請求項1に記載の方法。 - 前記個人用パラメータが、前記薬物投与に対する前記患者の予測される応答に関連することを特徴とする、
請求項1に記載の方法。 - 前記個人用パラメータが、前記患者の消化管内の特定の生体分子の分布、特にP−糖タンパク及び多剤耐性タンパクのようなATP結合カセット族のメンバの分布に関連することを特徴とする、
請求項1に記載の方法。 - 前記送達プロファイルが、時間及び/又は消化管内の場所に対する薬物吐出速度を有することを特徴とする、
請求項1に記載の方法。 - 前記薬物動態データ及び/又は患者応答が、特に前記電子ピルによる、前記薬物の投与中にサンプリングされることを特徴とする、
請求項1に記載の方法。 - 前記送達プロファイルが、前記薬物の投与の間及び/又は後に調節されることを特徴とする、
請求項1に記載の方法。 - 請求項1に記載の方法を実行することを可能にするコンピュータプログラム。
- ローカル又は広域電気通信ネットワーク上の請求項8に記載のコンピュータプログラムの送信。
- 患者に対する少なくとも1つの薬物の投与に対する電子ピルにおいて、薬物リザーバと、前記患者の少なくとも1つの個人用パラメータによって決定される送達プロファイルを用いて前記薬物リザーバからの前記薬物の制御される送達に対するコントローラとを有する電子ピル。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2944708P | 2008-02-18 | 2008-02-18 | |
US61/029,447 | 2008-02-18 | ||
PCT/IB2009/050553 WO2009104110A1 (en) | 2008-02-18 | 2009-02-11 | Administration of drugs to a patient |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017157752A Division JP2017221711A (ja) | 2008-02-18 | 2017-08-18 | 患者に対する薬物の投与 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2011512189A true JP2011512189A (ja) | 2011-04-21 |
JP6230772B2 JP6230772B2 (ja) | 2017-11-15 |
Family
ID=40521921
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010546431A Active JP6230772B2 (ja) | 2008-02-18 | 2009-02-11 | 患者に対する薬物の投与 |
JP2017157752A Pending JP2017221711A (ja) | 2008-02-18 | 2017-08-18 | 患者に対する薬物の投与 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017157752A Pending JP2017221711A (ja) | 2008-02-18 | 2017-08-18 | 患者に対する薬物の投与 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20100331827A1 (ja) |
EP (1) | EP2254464B1 (ja) |
JP (2) | JP6230772B2 (ja) |
CN (1) | CN101945613B (ja) |
WO (1) | WO2009104110A1 (ja) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012046166A1 (en) * | 2010-10-06 | 2012-04-12 | Koninklijke Philips Electronics N.V. | Electronic pill for delivery of powder medication |
WO2012129497A2 (en) * | 2011-03-24 | 2012-09-27 | MEDIMETRICS Personalized Drug Delivery B.V. | Swallowable medication capsule |
CN102567628A (zh) * | 2011-12-16 | 2012-07-11 | 广东省人民医院 | 一种药物代谢动力学采样和数据收集系统及方法 |
US10264972B2 (en) | 2012-05-21 | 2019-04-23 | International Business Machines Corporation | Dispensing drugs from a companion diagnostic linked smart pill |
US10045713B2 (en) | 2012-08-16 | 2018-08-14 | Rock West Medical Devices, Llc | System and methods for triggering a radiofrequency transceiver in the human body |
WO2014028902A1 (en) | 2012-08-16 | 2014-02-20 | Rock West Solutions, Inc. | System and methods for locating a radiofrequency transceiver in the human body |
US9955922B2 (en) * | 2012-11-16 | 2018-05-01 | Lowell Zane Shuck | Capsule device and methodology for discovery of gut microbe roles in diseases with origin in gut |
US9215997B2 (en) * | 2012-11-16 | 2015-12-22 | L. Zane Shuck | In vivo technology system for human gut research, diagnostics and treatment |
EP3060102B1 (en) | 2013-10-22 | 2021-03-24 | Rock West Medical Devices, LLC | System to localize swallowable pill sensor with three transmitting elements |
DK3197336T3 (da) * | 2014-09-25 | 2021-01-18 | Progenity Inc | Elektromekanisk pilleindretning med lokaliseringsegenskaber |
KR20240115384A (ko) | 2016-09-09 | 2024-07-25 | 비오라 쎄라퓨틱스, 인크. | 분배가능한 물질의 전달을 위한 전자기계식 섭취가능한 디바이스 |
WO2018112223A1 (en) | 2016-12-14 | 2018-06-21 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with a tlr modulator |
MX2019006821A (es) | 2016-12-14 | 2019-10-21 | Progenity Inc | Tratamiento de una enfermedad del tracto gastrointestinal con un inhibidor de cinasa de janus (jak) y dispositivos. |
CA3046023A1 (en) | 2016-12-14 | 2018-06-21 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunosuppressant |
CA3045475A1 (en) | 2016-12-14 | 2018-06-21 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor released using an ingestible device |
EP3600414A1 (en) | 2017-03-30 | 2020-02-05 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with il-10 or an il-10 agonist |
US11541015B2 (en) | 2017-05-17 | 2023-01-03 | Massachusetts Institute Of Technology | Self-righting systems, methods, and related components |
AU2018269704B2 (en) | 2017-05-17 | 2024-02-08 | Massachusetts Institute Of Technology | Self-righting systems, methods, and related components |
WO2019222570A1 (en) | 2018-05-17 | 2019-11-21 | Massachusetts Institute Of Technology | Systems for electrical stimulation |
EP3883635A1 (en) | 2018-11-19 | 2021-09-29 | Progenity, Inc. | Methods and devices for treating a disease with biotherapeutics |
CN113993560B (zh) | 2019-02-01 | 2024-05-07 | 麻省理工学院 | 用于液体注射的系统和方法 |
US11541216B2 (en) | 2019-11-21 | 2023-01-03 | Massachusetts Institute Of Technology | Methods for manufacturing tissue interfacing components |
CN115666704A (zh) | 2019-12-13 | 2023-01-31 | 比奥拉治疗股份有限公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006021932A1 (en) * | 2004-08-27 | 2006-03-02 | Koninklijke Philips Electronics, N.V. | Electronically and remotely controlled pill and system for delivering at least one medicament |
JP2007510970A (ja) * | 2003-10-02 | 2007-04-26 | バイエル・テクノロジー・サービシーズ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 活性物質の投与量の決定方法 |
WO2007072297A2 (en) * | 2005-12-22 | 2007-06-28 | Koninklijke Philips Electronics N.V. | Device for controlled release of chemical molecules |
WO2007148238A1 (en) * | 2006-06-20 | 2007-12-27 | Koninklijke Philips Electronics, N.V. | Electronic capsule for treating gastrointestinal disease |
Family Cites Families (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4564363A (en) * | 1983-07-13 | 1986-01-14 | Smithkline Beckman Corporation | Delayed action assembly |
US4572403A (en) * | 1984-02-01 | 1986-02-25 | Rafael Benaroya | Timed dispensing device for tablets, capsules, and the like |
US4814180A (en) * | 1984-03-21 | 1989-03-21 | Alza Corporation | Agent dispenser comprising a semipermeable wall surrounding single-piece or two-piece container |
US5071040A (en) * | 1990-03-09 | 1991-12-10 | Pfizer Hospital Products Group, Inc. | Surgical adhesives mixing and dispensing implement |
US5170801A (en) * | 1990-10-02 | 1992-12-15 | Glaxo Inc. | Medical capsule device actuated by radio-frequency (rf) signal |
US5279607A (en) * | 1991-05-30 | 1994-01-18 | The State University Of New York | Telemetry capsule and process |
US5318557A (en) * | 1992-07-13 | 1994-06-07 | Elan Medical Technologies Limited | Medication administering device |
US5423779A (en) * | 1993-11-02 | 1995-06-13 | Yeh; Charles R. | High efficiency filtration particulate and smoke evacuator system |
US5567592A (en) * | 1994-02-02 | 1996-10-22 | Regents Of The University Of California | Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal |
US5853386A (en) * | 1996-07-25 | 1998-12-29 | Alaris Medical Systems, Inc. | Infusion device with disposable elements |
GB9718903D0 (en) * | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents |
CA2304663C (en) * | 1997-10-02 | 2005-08-09 | Boston Scientific Limited | Device and method for delivering fiber into a body |
DE19849700C2 (de) * | 1998-10-28 | 2001-06-28 | Festo Ag & Co | Mikroventilanordnung |
US6300417B1 (en) * | 1998-12-22 | 2001-10-09 | The Texas A&M University System | Method for improving the impact resistance and scratch resistance of polymeric systems |
FI108813B (fi) * | 1999-03-08 | 2002-03-28 | Sonera Smarttrust Oy | Menetelmä ja järjestelmä tietoliikennejärjestelmässä |
ES2270834T3 (es) * | 1999-05-17 | 2007-04-16 | Cancer Research Ventures Limited | Composiciones para mejorar la biodisponibilidad de farmacos administrados oralmente. |
GB9930000D0 (en) * | 1999-12-21 | 2000-02-09 | Phaeton Research Ltd | An ingestible device |
US6699214B2 (en) * | 2000-01-19 | 2004-03-02 | Scimed Life Systems, Inc. | Shear-sensitive injectable delivery system |
EP1248595A4 (en) * | 2000-01-20 | 2006-06-14 | Delsys Pharmaceutical Corp | PHARMACEUTICAL FORMS FOR THE STEP BY STEP REDUCTION OF MEDICAMENTS |
WO2001062892A2 (en) * | 2000-02-25 | 2001-08-30 | Stratagene | Method for ligating nucleic acids and molecular cloning |
US8036731B2 (en) * | 2001-01-22 | 2011-10-11 | Spectrum Dynamics Llc | Ingestible pill for diagnosing a gastrointestinal tract |
US6929636B1 (en) * | 2000-11-08 | 2005-08-16 | Hewlett-Packard Development Company, L.P. | Internal drug dispenser capsule medical device |
US6632175B1 (en) * | 2000-11-08 | 2003-10-14 | Hewlett-Packard Development Company, L.P. | Swallowable data recorder capsule medical device |
US6734289B2 (en) * | 2001-03-29 | 2004-05-11 | The University Of Chicago | Gastrokines and derived peptides including inhibitors |
US7022475B2 (en) * | 2001-03-29 | 2006-04-04 | St. Jude Children's Research Hospital | Genotyping assay to predict CYP3A5 phenotype |
JP4744026B2 (ja) * | 2001-07-30 | 2011-08-10 | オリンパス株式会社 | カプセル内視鏡およびカプセル内視鏡システム |
JP2003325439A (ja) * | 2002-05-15 | 2003-11-18 | Olympus Optical Co Ltd | カプセル型医療装置 |
US6776165B2 (en) * | 2002-09-12 | 2004-08-17 | The Regents Of The University Of California | Magnetic navigation system for diagnosis, biopsy and drug delivery vehicles |
AU2003285756A1 (en) * | 2002-12-16 | 2004-07-09 | Given Imaging Ltd. | Device, system and method for selective activation of in vivo sensors |
US20040267240A1 (en) * | 2003-01-29 | 2004-12-30 | Yossi Gross | Active drug delivery in the gastrointestinal tract |
CA2514392A1 (en) * | 2003-01-29 | 2004-08-12 | E-Pill Pharma Ltd. | Active drug delivery in the gastrointestinal tract |
US20050058701A1 (en) * | 2003-01-29 | 2005-03-17 | Yossi Gross | Active drug delivery in the gastrointestinal tract |
US7014640B2 (en) * | 2003-03-28 | 2006-03-21 | Depuy Products, Inc. | Bone graft delivery device and method of use |
WO2004093812A2 (en) * | 2003-04-22 | 2004-11-04 | Irm Llc | Compounds that induce neuronal differentiation in embryonic stem cells |
JP2004350963A (ja) * | 2003-05-29 | 2004-12-16 | Olympus Corp | カプセル型医療装置 |
WO2005024687A1 (ja) * | 2003-09-02 | 2005-03-17 | Fujitsu Limited | 薬服用状況管理方法、薬剤及び薬服用状況管理装置 |
US7393924B2 (en) * | 2004-01-06 | 2008-07-01 | Franco Vitaliano | Smart bio-nanoparticle elements |
US7654985B2 (en) * | 2004-03-30 | 2010-02-02 | Given Imaging Ltd. | Controlled detachment of intra-luminal medical device |
US20060021932A1 (en) * | 2004-07-26 | 2006-02-02 | Darnell Justin R | Integrated flat panel filter and housing |
US7134909B2 (en) * | 2004-07-28 | 2006-11-14 | Fujitsu Limited | Connector circuit board |
US7098721B2 (en) * | 2004-09-01 | 2006-08-29 | International Business Machines Corporation | Low voltage programmable eFuse with differential sensing scheme |
SE0402169L (sv) * | 2004-09-10 | 2005-07-26 | Car O Liner Ab | Kombinerad ramp- och pallbockskonstruktion |
US8100889B2 (en) * | 2004-11-10 | 2012-01-24 | Olympus Corporation | Body-insertable apparatus |
JP2008521794A (ja) * | 2004-11-29 | 2008-06-26 | コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ | 少なくとも一の薬剤を輸送するための、少なくとも一のセンサを有する電子制御式の錠剤およびシステム |
JP2008526418A (ja) * | 2005-01-18 | 2008-07-24 | コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ | 放射線を放出するための電子制御されるカプセル |
WO2006086479A2 (en) * | 2005-02-09 | 2006-08-17 | Children's Medical Center Corporation | Device for mixing and delivering fluids for tissue repair |
US8021357B2 (en) * | 2005-05-27 | 2011-09-20 | Olympus Corporation | Body-insertable apparatus |
WO2007002516A2 (en) * | 2005-06-23 | 2007-01-04 | Spherics, Inc. | Improved dosage forms for movement disorder treatment |
US8728289B2 (en) * | 2005-12-15 | 2014-05-20 | Medtronic, Inc. | Monolithic electrodes and pH transducers |
US20080099356A1 (en) * | 2006-10-31 | 2008-05-01 | Calyx & Corolla, Inc. | Flower shipment packaging |
WO2008099356A2 (en) * | 2007-02-15 | 2008-08-21 | Koninklijke Philips Electronics N.V. | Drug delivery device |
-
2009
- 2009-02-11 CN CN200980105514.0A patent/CN101945613B/zh active Active
- 2009-02-11 US US12/867,888 patent/US20100331827A1/en not_active Abandoned
- 2009-02-11 WO PCT/IB2009/050553 patent/WO2009104110A1/en active Application Filing
- 2009-02-11 JP JP2010546431A patent/JP6230772B2/ja active Active
- 2009-02-11 EP EP09712414.3A patent/EP2254464B1/en active Active
-
2017
- 2017-08-18 JP JP2017157752A patent/JP2017221711A/ja active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007510970A (ja) * | 2003-10-02 | 2007-04-26 | バイエル・テクノロジー・サービシーズ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 活性物質の投与量の決定方法 |
WO2006021932A1 (en) * | 2004-08-27 | 2006-03-02 | Koninklijke Philips Electronics, N.V. | Electronically and remotely controlled pill and system for delivering at least one medicament |
JP2008510558A (ja) * | 2004-08-27 | 2008-04-10 | コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ | 少なくとも1つの薬剤を投与する、電子制御され、遠隔制御されるピル及びシステム |
WO2007072297A2 (en) * | 2005-12-22 | 2007-06-28 | Koninklijke Philips Electronics N.V. | Device for controlled release of chemical molecules |
WO2007148238A1 (en) * | 2006-06-20 | 2007-12-27 | Koninklijke Philips Electronics, N.V. | Electronic capsule for treating gastrointestinal disease |
Also Published As
Publication number | Publication date |
---|---|
CN101945613A (zh) | 2011-01-12 |
EP2254464B1 (en) | 2017-01-04 |
JP2017221711A (ja) | 2017-12-21 |
US20100331827A1 (en) | 2010-12-30 |
CN101945613B (zh) | 2014-08-13 |
JP6230772B2 (ja) | 2017-11-15 |
WO2009104110A1 (en) | 2009-08-27 |
EP2254464A1 (en) | 2010-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6230772B2 (ja) | 患者に対する薬物の投与 | |
US20180296814A1 (en) | Administration of drugs to a patient | |
EP3554346B1 (en) | Treatment of a disease of the gastrointestinal tract with an immunosuppressant | |
JP7150724B2 (ja) | 消化管疾病のtnf阻害薬による治療 | |
JP7237834B2 (ja) | 消化管疾病のil-12/il-23阻害薬による治療 | |
JP2017221711A5 (ja) | ||
JP2022177262A5 (ja) | ||
CN101472639A (zh) | 用于治疗胃肠疾病的电子胶囊 | |
US11576860B2 (en) | Retrieval systems and related methods | |
WO2019147824A1 (en) | Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor | |
US20230312700A1 (en) | Treatment of a disease of the gastrointestinal tract with a tnf inhibitor | |
US10905661B2 (en) | Disulfiram and metal salt staggered oral dosing regimen and staggered-release oral unit dosage forms | |
US20170087299A1 (en) | Carrier apparatus to deliver a substance and methods thereof | |
EP3723801B9 (en) | Treatment of a disease of the gastrointestinal tract with a s1p modulator | |
US20230041197A1 (en) | Treatment of a disease of the gastrointestinal tract with an immunomodulator | |
Huntsman et al. | Development of a novel drug delivery system to deliver drugs directly to the colonic mucosa, resulting in improved efficacy and reduced systemic exposure for the treatment of ulcerative colitis | |
Ogawa et al. | Moderate renal dysfunction may not require a cisplatin dose reduction: a retrospective study of cancer patients with renal impairment | |
Grogan et al. | Definition/Introduction | |
Chen et al. | Application and safety of externally controlled metronomic drug delivery to the brain by an implantable smart pump in a sheep model | |
US20140221963A1 (en) | Use of eating detection to control the release of biologically active agents | |
Perpiñán | Insulinoma in ferrets: diagnosis and management | |
Zeitlinger | Drug interactions medicine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20111111 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20111125 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120209 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20130411 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130430 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130725 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140128 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140425 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20140522 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140528 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140611 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140619 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140514 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20140910 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141022 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20150331 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150731 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20150810 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20151106 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160927 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20161026 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20161125 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161226 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170619 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20170714 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170718 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170719 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20170714 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170818 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20171018 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6230772 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |